What the research found

Intermittent energy restriction (a pattern of eating where you consume fewer calories on certain days or periods) improved both fatty liver disease and blood sugar control in people with both conditions simultaneously. The researchers traced part of this benefit to changes in the gut microbiome—specifically, a reduction in Klebsiella pneumoniae, a bacterium that produces endotoxin (LPS), a pro-inflammatory molecule that enters the bloodstream and can trigger metabolic dysfunction.

In mouse models and laboratory cells, the team identified a specific protein modification in liver cells as central to the effect. A protein called HADHA, which helps metabolize fats, was less "acetylated" (chemically modified) after the dietary intervention, and this change made the protein work more efficiently. When they engineered cells to mimic this change, it reduced fat accumulation and inflammation even when exposed to bacterial endotoxin.

Why it matters for you

If you're tracking fasting glucose, triglycerides, or liver enzymes as part of your health optimisation, this suggests intermittent energy restriction may move multiple needles at once—particularly if you have overlap between metabolic syndrome markers and fatty liver indicators. The mechanism points to something measurable: bacterial endotoxin (LPS) levels can be tested, and future protocols might measure this as a proxy for whether your gut microbiome is shifting in a favourable direction.

For those using supplements or peptides aimed at metabolic health, this work hints that gut bacterial composition is a upstream lever—perhaps worth monitoring through microbiome testing or tracking inflammatory biomarkers (CRP, TNF-α) that correlate with endotoxin burden. The HADHA protein itself isn't something you'd test directly, but improvements in liver fat (via ultrasound or FibroScan) and fasting triglycerides reflect the functional outcome the researchers observed.

Caveats

• Mouse model: The core mechanistic work used db/db mice and cell culture; human evidence for the HADHA acetylation pathway is not yet shown
• Early-stage: The specific bacterial-endotoxin-protein modification chain is proposed but not fully validated in human studies
• Comorbidity-specific: Results apply to people with both fatty liver and type 2 diabetes; unclear if the same mechanism applies to either condition alone
• Intermittent restriction type unclear: The exact protocol (time-restricted eating, alternate-day fasting, 5:2 pattern) isn't detailed in this summary